Eterna Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 1993
Net Income	-22.9	-21.68	-24.6	-122.56	-7.29	-2.06	Upgrade
Depreciation & Amortization	1.6	1.12	0.5	0.46	0.1	3.17	Upgrade
Share-Based Compensation	0.84	1.24	2.94	5.24	0.09	0.21	Upgrade
Other Operating Activities	2.36	-1.11	0.17	93.36	-1	1.42	Upgrade
Operating Cash Flow	-18.11	-20.41	-20.98	-23.49	-8.1	2.74	Upgrade
Operating Cash Flow Growth	-	-	-	-	-	101.03%	Upgrade
Capital Expenditures	-0.12	-0.02	-0.05	-0.15	-0.04	-1.09	Upgrade
Acquisitions	0	0	0	-22.59	0	0	Upgrade
Other Investing Activities	-	-	-	-	-	0.03	Upgrade
Investing Cash Flow	-0.12	-0.02	-0.05	-22.74	-0.04	-1.07	Upgrade
Share Issuance / Repurchase	0.32	0.32	19.6	62.54	4.36	0	Upgrade
Debt Issued / Paid	16.23	16.25	-0	-0.94	0.31	-1.05	Upgrade
Other Financing Activities	1.39	-0.02	-0.01	-0.01	-	-0.05	Upgrade
Financing Cash Flow	17.94	16.56	19.58	61.59	4.67	-1.1	Upgrade
Exchange Rate Effect	0	0	0	0	0	0.04	Upgrade
Net Cash Flow	-0.28	-3.87	-1.44	15.36	-3.47	0.62	Upgrade
Free Cash Flow	-18.22	-20.43	-21.02	-23.64	-8.14	1.65	Upgrade
Free Cash Flow Margin	-15845.22%	-30039.71%	-	-	-	8.33%	Upgrade
Free Cash Flow Per Share	-3.37	-3.84	-6.89	-10.92	-9.26	22.96	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).